WPP Q1 Revenue Down 4.9%

By RTTNews Staff Writer ✉ | Published: 4/29/2020 2:35 AM ET

WPP plc (WPP.L,WPPGY) reported that its revenue from continuing operations for the first quarter of 2020 was 2.8 billion pounds, down 4.9% from last year on a reported basis and down 4.6% on a constant currency basis.

On a like-for-like basis, revenue was down 3.8% compared with last year.

Revenue less pass-through costs was 2.4 billion pounds, down 4.3% on a reported basis, or 4.0% in constant currency and or 3.3% LFL.

The company expects the impact of COVID-19 on its business to increase in the short term, but it is not possible to quantify the depth or duration of the impact.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In July 2020

New Drugs Approved In May

Biotech Stocks Facing FDA Decision In June 2020

Editors Pick

Cottage Town Bedroom Furniture Collection Recalled For Lead Concerns

Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard.

Sanofi, Regeneron Stop Kevzara COVID-19 Trial In U.S. After Failing To Meet Key Goals

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.

Moderna Reportedly Delays Phase 3 Trial Of COVID-19 Vaccine

Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...